MedTrace Logo

A Pilot Study of KRX-0502 (Ferric Citrate, Administered Without Food, in Treating Iron-deficiency Anemia

NCT02128074 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 32

Last updated 2018-08-24

Study results available
· View outcomes & findings →

Summary

The objective of the study is to evaluate the efficacy and safety of KRX-0502, administered without food, in treating iron deficiency anemia in subjects with stage 3 to 5 non-dialysis dependent chronic kidney disease (NDD-CKD).

Conditions

  • Anemia of Chronic Kidney Disease

Interventions

DRUG

KRX-0502

1g tablets of KRX-0502

Sponsors & Collaborators

  • Keryx Biopharmaceuticals

    lead INDUSTRY

Principal Investigators

  • Yoram Yagil, MD · The Barzilai Medical Center

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-04-30
Primary Completion
2014-11-30
Completion
2014-11-30

Countries

  • Israel

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02128074 on ClinicalTrials.gov